Compare MEDP & DECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEDP | DECK |
|---|---|---|
| Founded | 1992 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 14.2B |
| IPO Year | 2016 | 1996 |
| Metric | MEDP | DECK |
|---|---|---|
| Price | $536.08 | $106.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 23 |
| Target Price | ★ $473.17 | $122.45 |
| AVG Volume (30 Days) | 312.5K | ★ 1.9M |
| Earning Date | 04-22-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.98 | 10.90 |
| EPS | 4.28 | ★ 7.02 |
| Revenue | N/A | ★ $5,472,296,000.00 |
| Revenue This Year | $13.19 | $11.16 |
| Revenue Next Year | $7.75 | $6.96 |
| P/E Ratio | $124.98 | ★ $15.52 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $306.70 | $78.91 |
| 52 Week High | $628.92 | $126.50 |
| Indicator | MEDP | DECK |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 50.58 |
| Support Level | $525.92 | $105.13 |
| Resistance Level | $622.32 | $115.40 |
| Average True Range (ATR) | 16.95 | 3.39 |
| MACD | -2.69 | 0.41 |
| Stochastic Oscillator | 36.47 | 62.17 |
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.